RCEL (AVITA Medical, Inc) Short-Term Debt to Capital

AVITA Medical, Inc. (RCEL) maintains absolute authority in the field of tissue restoration. Market valuation data on GURU.Markets shows that the indicator stands at 0.00. The business relies on autologous cell spraying technology, which creates clinic dependency on high-cost consumables. Stability is ensured by US-based manufacturing plants and the recognition of the method as the gold standard for treating severe skin damage.

The ratio is calculated as the proportion of liabilities with a maturity of more than one year to the company's equity. This metric determines the business's dependence on long-term debt financing, where increasing values indicate a risk of liquidity loss. For AVITA Medical, Inc. (RCEL), the effective commercialization of the RECELL system allows the company to balance its debt load with expansion. An analysis of the share of short-term loans in equity confirms the financial stability of management's market capture strategy.